Maternal immunoglobulin treatment can reduce severity of fetal acetylcholine receptor antibody-associated disorders (FARAD)

BACKGROUND: Fetal acetylcholine receptor antibody-associated disorders (FARAD), caused by in utero exposure to maternal antibodies directed against the fetal acetylcholine receptor (AChR), is a rare condition occurring in newborns of myasthenic mothers. Only two cases of FARAD children born to asymp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wassenberg, Matthias, Hahn, Andreas, Mück, Anna, Krämer, Heidrun H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601289/
https://www.ncbi.nlm.nih.gov/pubmed/37880783
http://dx.doi.org/10.1186/s42466-023-00280-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601289/
https://www.ncbi.nlm.nih.gov/pubmed/37880783
http://dx.doi.org/10.1186/s42466-023-00280-6

Ejemplares similares